Eric Blount

Array ( [id] => 13957677 [patent_doc_number] => 20190055182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => ASYMMETRIC CATALYTIC DECARBOXYLATIVE ALKYL ALKYLATION USING LOW CATALYST CONCENTRATIONS AND A ROBUST PRECATALYST [patent_app_type] => utility [patent_app_number] => 16/166893 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16166893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309525 [patent_doc_number] => 20190144466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => MAX BINDERS AS MYC MODULATORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/167238 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40892 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16167238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185127 [patent_doc_number] => 20190112268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => mTORC1 MODULATORS [patent_app_type] => utility [patent_app_number] => 16/159380 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57712 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 475 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16159380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17587660 [patent_doc_number] => 11325915 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-10 [patent_title] => Lysyl oxidase inhibitors [patent_app_type] => utility [patent_app_number] => 16/755739 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53355 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 840 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17044878 [patent_doc_number] => 11098046 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-24 [patent_title] => Macrocyclic compounds as TRK kinase inhibitors and uses thereof [patent_app_type] => utility [patent_app_number] => 16/760790 [patent_app_country] => US [patent_app_date] => 2018-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18813 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 250 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16760790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17800115 [patent_doc_number] => 11414395 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => Heterocyclic compounds as modulators of mGluR7 [patent_app_type] => utility [patent_app_number] => 16/650817 [patent_app_country] => US [patent_app_date] => 2018-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41114 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 428 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156461 [patent_doc_number] => 20200216463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => THAILANSTATIN ANALOGS [patent_app_type] => utility [patent_app_number] => 16/648991 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826493 [patent_doc_number] => 20190016731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/135512 [patent_app_country] => US [patent_app_date] => 2018-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22673 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16135512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18620382 [patent_doc_number] => 11753410 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-12 [patent_title] => Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders [patent_app_type] => utility [patent_app_number] => 16/647385 [patent_app_country] => US [patent_app_date] => 2018-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70642 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 214 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13777829 [patent_doc_number] => 20190002453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => INHIBITORS OF BETA-HYDROXYLASE FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/131275 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24095 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 490 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16131275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185227 [patent_doc_number] => 20190112318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => COMPOUNDS, COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/130817 [patent_app_country] => US [patent_app_date] => 2018-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 112757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16130817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15062269 [patent_doc_number] => 10461449 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-29 [patent_title] => Methods for the acylation of maytansinol [patent_app_type] => utility [patent_app_number] => 16/129268 [patent_app_country] => US [patent_app_date] => 2018-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5975 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16129268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043371 [patent_doc_number] => 20190077792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => Octahydrocyclopenta[c]pyrrole Allosteric Inhibitors of SHP2 [patent_app_type] => utility [patent_app_number] => 16/127772 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26240 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 274 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16127772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15880505 [patent_doc_number] => 10646577 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => mTORC1 inhibitors [patent_app_type] => utility [patent_app_number] => 16/126210 [patent_app_country] => US [patent_app_date] => 2018-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 22 [patent_no_of_words] => 57994 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 526 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16126210 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16326800 [patent_doc_number] => 20200297765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => MODIFIED IMMUNE CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/645727 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16645727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17330053 [patent_doc_number] => 11220506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-11 [patent_title] => Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors [patent_app_type] => utility [patent_app_number] => 16/643040 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24247 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 582 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17323551 [patent_doc_number] => 11214545 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-04 [patent_title] => Industrial process of mono-alkylating piperidine nitrogen in piperidine derivative with deuterated-lower-alkyl [patent_app_type] => utility [patent_app_number] => 16/644084 [patent_app_country] => US [patent_app_date] => 2018-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7101 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16644084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15006203 [patent_doc_number] => 10449207 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-22 [patent_title] => Acyclic nucleoside phosphonate diesters [patent_app_type] => utility [patent_app_number] => 16/111378 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 28144 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15540779 [patent_doc_number] => 10570154 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders [patent_app_type] => utility [patent_app_number] => 16/108725 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 7 [patent_no_of_words] => 18086 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16108725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18215219 [patent_doc_number] => 11590132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Pyruvate kinase activators for use in treating blood disorders [patent_app_type] => utility [patent_app_number] => 16/639081 [patent_app_country] => US [patent_app_date] => 2018-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 2 [patent_no_of_words] => 33877 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 339 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639081 [rel_patent_id] =>[rel_patent_doc_number] =>)